Literature DB >> 8571992

Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.

G G Bon1, P Kenemans, R Verstraeten, G J van Kamp, J Hilgers.   

Abstract

OBJECTIVE: Our purpose was to establish reference values for six monoclonal antibody-based serum immunoassays applied in patients with carcinoma of the female genital tract. STUDY
DESIGN: Sera from 938 healthy women (median age 48.0 years, range 37 to 76 years) were assayed for levels of CA 125, CA 15.3 (two methods), CA M29, CA M26, and mucin-like cancer antigen (MCA).
RESULTS: Reference values, defined as those including 95% of healthy controls, were in women with unknown menopausal status as follows: CA 125, 37 U/ml; CA 15.3 (Centocor), 33 U/ml; CA 15.3 (Boehringer Mannheim), 28 U/ml; CA M26, 83 U/ml; CA M29, 13 U/ml; and MCA, 19 U/ml. Postmenopausal values were significantly lower for CA 125 and CA M26 and significantly higher for CA M29 and CA 15.3 (both methods). MCA serum levels were age independent.
CONCLUSION: Reference values found were not in accord with those generally applied in gynecologic oncology. In addition, serum levels were influenced significantly by menopausal status (except with MCA).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8571992     DOI: 10.1016/s0002-9378(96)70381-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  17 in total

1.  The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.

Authors:  Christine C Johnson; Bruce Kessel; Thomas L Riley; Lawrence R Ragard; Craig R Williams; Jian-Lun Xu; Saundra S Buys
Journal:  Gynecol Oncol       Date:  2008-06-30       Impact factor: 5.482

2.  Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.

Authors:  Elisabetta Bandiera; Chiara Romani; Claudia Specchia; Laura Zanotti; Claudio Galli; Giuseppina Ruggeri; Germana Tognon; Eliana Bignotti; Renata A Tassi; Franco Odicino; Luigi Caimi; Enrico Sartori; Alessandro D Santin; Sergio Pecorelli; Antonella Ravaggi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10-25       Impact factor: 4.254

Review 3.  The roles of second-look laparotomy and cancer antigen 125 in the management of ovarian carcinoma.

Authors:  A E Selman; L J Copeland
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

4.  Rhizoctonia bataticola lectin induces apoptosis and inhibits metastasis in ovarian cancer cells by interacting with CA 125 antigen differentially expressed on ovarian cells.

Authors:  Prajna Hegde; Sindhura B R; Suhas Ballal; Bale M Swamy; Shashikala R Inamdar
Journal:  Glycoconj J       Date:  2021-11-08       Impact factor: 2.916

Review 5.  Current state of biomarker development for clinical application in epithelial ovarian cancer.

Authors:  Richard G Moore; Shannon MacLaughlan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2009-10-31       Impact factor: 5.482

6.  Application of carbon nanotubes layered on silicon wafer for the detection of breast cancer marker carbohydrate antigen 15-3 by immuno-polymerase chain reaction.

Authors:  S Sadhasivam; Jung-Chih Chen; S Savitha; Chun-Wei Chang; Feng-Huei Lin
Journal:  J Mater Sci Mater Med       Date:  2013-10-01       Impact factor: 3.896

7.  Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.

Authors:  Naoko Sasamoto; Allison F Vitonis; Raina N Fichorova; Hidemi S Yamamoto; Kathryn L Terry; Daniel W Cramer
Journal:  Cancer Causes Control       Date:  2021-01-18       Impact factor: 2.506

8.  HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

Authors:  T Van Gorp; I Cadron; E Despierre; A Daemen; K Leunen; F Amant; D Timmerman; B De Moor; I Vergote
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

9.  Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses.

Authors:  Farah Farzaneh; Zahra Honarvar; Mansoore Yaraghi; Mehdi Yaseri; Maliheh Arab; Maryamsadat Hosseini; Tahereh Ashrafgangoi
Journal:  Iran Red Crescent Med J       Date:  2014-06-05       Impact factor: 0.611

Review 10.  Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.

Authors:  Santosh Kumar Behera; Ardhendu Bhusan Praharaj; Budheswar Dehury; Sapna Negi
Journal:  Glycoconj J       Date:  2015-08-04       Impact factor: 3.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.